Shionogi

SGIOY

$15.73B

Large Cap

NASDAQHealthcare🇺🇸North America5.0K employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 31, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

Redasemtide Phase 2 Results Expected

Mar 31, 2026Redasemtide680

Primary completion for Redasemtide trial (NCT05953480) in Acute Ischemic Stroke

Source

Phase 2

Naldemedine Phase 2 Results Expected

Jun 15, 2026Naldemedine24

Primary completion for Naldemedine trial (NCT05588323) in Opioid-Induced Constipation (OIC)

Source

Phase 2

S-337395 Phase 2 Results Expected

Dec 30, 2026S-337395192

Primary completion for S-337395 trial (NCT07214571) in Respiratory Syncytial Virus Infections

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Duloxetine Hydrochloride

Phase 3

Depressive Disorder

Ospemifene 60Mg Oral Tablet

Phase 3

Atrophy

Ospemifene (Dose 1)

Phase 3

Atrophy

Ospemifene 30 mg

Phase 3

Atrophy

Oral Glycopyrrolate Liquid

Phase 3

Cerebral Palsy

Meropenem

Phase 3

Healthcare-associated Pneumonia (HCAP)

Ospemifene 60 mg

Phase 3

Atrophy

Cefiderocol

Phase 3

Urinary Tract Infections

Ospemifene

Phase 3

Vaginal Dryness

Lusutrombopag

Phase 3

Chronic Liver Disease

S-217622

Phase 3

SARS-CoV-2 Infection

Baloxavir Marboxil

Phase 3

Influenza

CLONICEL (Clonidine HCl sustained release)

Phase 3

Attention Deficit Hyperactivity Disorder

S-268019-b

Phase 3

SARS-CoV-2

Pravafen

Phase 3

Combined Hyperlipidemia

Best Available Therapy

Phase 3

Healthcare-associated Pneumonia (HCAP)

Naldemedine

Phase 3

Opioid-induced Constipation

Oseltamivir

Phase 3

Influenza

Velneperit 400 mg

Phase 2

Obesity

S-2367 800 mg

Phase 2

Obesity

S-2367 1600 mg q.d. 54 Weeks

Phase 2

Obesity

Redasemtide

Phase 2

Acute Ischemic Stroke

S-606001

Phase 2

Pompe Disease

S-555739 Dose 1

Phase 2

Seasonal Allergic Rhinitis

BPN14770

Phase 2

Jordan's Syndrome

S-707106 Dose A

Phase 2

Type 2 Diabetes Mellitus

Sivopixant

Phase 2

Sleep Apnea

S-600918

Phase 2

Chronic Cough

S-309309

Phase 2

Obesity

50 mg S-777469

Phase 2

Atopic Dermatitis

S-892216

Phase 2

COVID-19

S-777469 400 mg

Phase 2

Atopic Dermatitis

S-2367 (velneperit)

Phase 2

Obesity

Ospemifene 5 mg

Phase 2

Atrophy

S-337395

Phase 2

Respiratory Syncytial Virus Infections

S-531011

Phase 2

Solid Tumors

S-3304

Phase 2

Non Small Cell Lung Cancer

Standard of Care

Phase 2

Gram-negative Bacterial Infections

Drug Name	Phase	Indication	Designations
Duloxetine Hydrochloride	Phase 3	Depressive Disorder	-
Ospemifene 60Mg Oral Tablet	Phase 3	Atrophy	-
Ospemifene (Dose 1)	Phase 3	Atrophy	-
Ospemifene 30 mg	Phase 3	Atrophy	-
Oral Glycopyrrolate Liquid	Phase 3	Cerebral Palsy	-
Meropenem	Phase 3	Healthcare-associated Pneumonia (HCAP)	-
Ospemifene 60 mg	Phase 3	Atrophy	-
Cefiderocol	Phase 3	Urinary Tract Infections	-
Ospemifene	Phase 3	Vaginal Dryness	-
Lusutrombopag	Phase 3	Chronic Liver Disease	-
S-217622	Phase 3	SARS-CoV-2 Infection	-
Baloxavir Marboxil	Phase 3	Influenza	-
CLONICEL (Clonidine HCl sustained release)	Phase 3	Attention Deficit Hyperactivity Disorder	-
S-268019-b	Phase 3	SARS-CoV-2	-
Pravafen	Phase 3	Combined Hyperlipidemia	-
Best Available Therapy	Phase 3	Healthcare-associated Pneumonia (HCAP)	-
Naldemedine	Phase 3	Opioid-induced Constipation	-
Oseltamivir	Phase 3	Influenza	-
Velneperit 400 mg	Phase 2	Obesity	-
S-2367 800 mg	Phase 2	Obesity	-
S-2367 1600 mg q.d. 54 Weeks	Phase 2	Obesity	-
Redasemtide	Phase 2	Acute Ischemic Stroke	-
S-606001	Phase 2	Pompe Disease	-
S-555739 Dose 1	Phase 2	Seasonal Allergic Rhinitis	-
BPN14770	Phase 2	Jordan's Syndrome	-
S-707106 Dose A	Phase 2	Type 2 Diabetes Mellitus	-
Sivopixant	Phase 2	Sleep Apnea	-
S-600918	Phase 2	Chronic Cough	-
S-309309	Phase 2	Obesity	-
50 mg S-777469	Phase 2	Atopic Dermatitis	-
S-892216	Phase 2	COVID-19	-
S-777469 400 mg	Phase 2	Atopic Dermatitis	-
S-2367 (velneperit)	Phase 2	Obesity	-
Ospemifene 5 mg	Phase 2	Atrophy	-
S-337395	Phase 2	Respiratory Syncytial Virus Infections	-
S-531011	Phase 2	Solid Tumors	-
S-3304	Phase 2	Non Small Cell Lung Cancer	-
Standard of Care	Phase 2	Gram-negative Bacterial Infections	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

SGIOY News